- Home
- SRTS vs BCTX Comparison
SRTS vs BCTX Comparison
Compare SRTS & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRTS | BCTX |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.6M | 36.6M |
| IPO Year | 2016 | 2025 |
Fundamental Metrics
Financial Performance| Metric | SRTS | BCTX |
|---|---|---|
| Price | $2.83 | $3.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.38 | N/A |
| AVG Volume (30 Days) | 15.8K | ★ 54.3K |
| Earning Date | 11-09-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,482,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $41.11 | $380.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.66 | $2.60 |
| 52 Week High | $5.49 | $13.09 |
Technical Indicators
Market Signals| Indicator | SRTS | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.48 | 40.99 |
| Support Level | $2.75 | $3.35 |
| Resistance Level | $3.17 | $3.74 |
| Average True Range (ATR) | 0.13 | 0.22 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 27.78 | 21.02 |
Price Performance
Historical ComparisonAbout SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.